Form 4: Vertex Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Bruce I. Sachs, a director at Vertex Pharmaceuticals, acquired 3,142 stock options at a price of $399.71 on May 1, 2024.
Summary
- On May 1, 2024, Bruce I. Sachs, a director of Vertex Pharmaceuticals, acquired 3,142 stock options.
- The exercise price of these options is $399.71.
- The options are fully vested and expire on April 30, 2034.
- Following the transaction, Sachs directly owns 3,142 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event, simply a director exercising or being granted stock options, which is a common practice.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders, as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of stock option acquisition |
| 04/30/2034 | Expiration date of the stock options |
| 05/03/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.